Q2 2023 Financial Results & Business Update August 8, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking stateme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551 ___________________________ Acumen Pharmaceuticals, ...

Financial Data and Key Metrics Changes - As of March 31, 2023, the company had approximately $184 million in cash and marketable securities, with expectations that this cash will last through 2025 [16] - R&D expenses for Q1 2023 were approximately $8.7 million, an increase attributed to heightened activity in the ongoing INTERCEPT-AD trial [16] - G&A expenses were $4.4 million, reflecting an increase due to higher headcount to support the INTERCEPT-AD trial, leading to a loss from operations of $13.1 million for the quarter [16] Business Line Data and Key Metrics Changes - The completion of enrollment in the Phase I INTERCEPT-AD trial for ACU193 was highlighted, with top-line results expected in Q3 2023 [6][7] - The company is preparing for Phase II/III activities, anticipating successful results from the Phase I study, with an end-of-Phase II meeting with the FDA expected in Q4 [8] Market Data and Key Metrics Changes - The evolving Alzheimer's landscape is noted, with positive momentum anticipated from upcoming outcomes related to lecanemab and donanemab, which may influence market access and uptake for ACU193 [8][9] Company Strategy and Development Direction - The company aims to develop ACU193 as a next-generation therapeutic for Alzheimer's patients, focusing on selective targeting of toxic A-beta oligomers [6][9] - There is an emphasis on the importance of the INTERCEPT-AD trial data for finalizing the design of subsequent studies, including dose selection [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ACU193 to have lower rates of ARIA-E compared to existing therapies, while also highlighting the need for further research to validate these claims [15] - The company is optimistic about the upcoming top-line data from the INTERCEPT-AD trial, which is expected to provide critical insights into safety and efficacy [16] Other Important Information - The company presented findings at AD/PD regarding the utility of a human in vitro model for understanding A-beta oligomers' role in Alzheimer's pathogenesis [12][13] - Management discussed the complexities of conducting head-to-head trials with other A-beta antibodies, indicating that such studies may not be required by regulatory agencies [27][28] Q&A Session Summary Question: Scenarios for Phase II study design - Management indicated that various factors, including primary outcomes and biomarkers, will be considered to decide whether to expand the study to Phase III [20][21] Question: Target engagement and oligomer concentrations - Management acknowledged the ongoing learning about toxic species and emphasized that clinical data will ultimately provide the necessary proof of ACU193's effectiveness [24] Question: Inclusion of comparator or combination arms in trials - Management noted that head-to-head trials are complex and not expected to be required, while also discussing the potential for combination therapies in future studies [27][28][43] Question: Cash runway and financing needs - Management expressed confidence that current cash will last through 2025, but acknowledged that financing may be necessary for future trials beyond that point [30] Question: Updates on PK/PD or safety before Q3 - Management stated that no new disclosures are anticipated prior to the topline results in Q3, but they are comfortable with the current safety profile [39]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551 ___________________________ Acumen Pharmaceuticals ...

1 FY 2022 Financial Results & Business Update March 27, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential, ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and Chief Executive Officer Eric Siemers - , Chief Medical Officer Matt Zuga - Chief Financial Officer and Chief Business Office Conference Call Participants Paul Matteis - Stifel Tom Shrader - BTIG Judah Frommer - Credit Suisse Operator Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-40551 __________________________ Acumen Pharmaceuticals, Inc. (Exact name of registrant ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - CMO Matt Zuga - CFO and CBO Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - Bank of America Operator Good day. Thank you for standing by. Welcome to the Acumen Pharmaceuticals, Q3 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mo ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, par value $0.0001 per share ABOS The Nasdaq Global Select Market Emerging growth company ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...